GA SB631

Authorizes the Georgia Department of Public Health to award grants for FDA-approved clinical trials using ibogaine as an investigational new drug to treat opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions in veterans

Requires grant recipients to be Georgia-based entities with neurosurgery programs, cardiac intensive care capabilities, and proven expertise in treating veterans' neurological conditions and substance dependence

Mandates that applicants demonstrate at least $7 million in matching funds from non-state sources and agree to join a multistate consortium that will submit an investigational new drug application and request breakthrough therapy designation from the FDA

Requires all intellectual property rights and commercial revenues arising from the funded clinical trials to be deposited into the state general fund

Contingent on General Assembly appropriations; the Act will be automatically repealed if funds are not appropriated by July 1, 2029